Ash Communications Healthcare has secured a contract to promote EMIG, which represents the views of small to medium-sized biopharma firms to government and trade bodies like the Association of the British Pharmaceutical Industry (ABPI).
It is currently campaigning to maintain the status quo of so-called 'standard' branded generic medicines within the Pharmaceutical Price Regulation Scheme, an issue under government review.
EMIG was formed around 20 years ago and has 45 member firms, including Leo Pharma and Ashbourne Pharmaceuticals.
Chairman Neil Symmonds said: 'Ash is supporting our aim to work with organisations such as the ABPI to ensure understanding of the challenges faced by our members in an increasingly difficult environment.'
Director Carys Thomas Ampofo leads the account at Ash.